FDA grants EUA for Lucira Health’s COVID-19 and flu combination test

Covid Treatment Doctor Social

Lucira Health on Tuesday announced that the U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for its molecular point-of-care COVID-19 & Flu Test.

Lucira said COVID-19 & Flu is a nucleic acid amplification test (NAAT) that can detect and differentiate COVID-19, influenza A, and influenza B. The single-use, battery-operated test delivers results within 30 minutes from a shallow nasal swab, without requiring a separate reader or instrument.

“Clinicians can now facilitate simultaneous rapid testing at a mass scale to get patients on the path to recovery quickly,” Erik Engelson, president and CEO of Lucira, said in a statement.

Page 1 of 24
Next Page